ATRICURE, INC. (NASDAQ:ATRC) Files An 8-K Results of Operations and Financial Condition


ATRICURE, INC. (NASDAQ:ATRC) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition.

On July 27, 2017, AtriCure, Inc.issued a press release regarding its financial results for the secondquarter ended June 30, 2017. The Company will hold a conference call on July 27, 2017 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 of Form 8-K and in the press release attached as Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Form 8-K and Exhibit 99.1 shall not be incorporated by reference in any filing or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing or document.

Item 2.02Financial Statements and Exhibits.






Press Release dated July 27, 2017relating tofinancial results for the first quarter ended June 30, 2017

AtriCure, Inc. Exhibit
EX-99.1 2 atrc-20170727xex99_1.htm EX-99.1 Exhibit 991     Exhibit 99.1  For immediate release July 27,…
To view the full exhibit click here


AtriCure, Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. Its Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion.